

Company Overview

Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms.

Kane Biotech Announces Third Quarter 2021 Financial Results

Nov 16 2021, 4:00 PM EST

Kane Biotech to Release Third Quarter 2021 Financial Results on November 16 – Conference Call to Follow

Nov 9 2021, 8:00 AM EST

Kane Biotech Announces New Credit Facility

Sep 2 2021, 8:00 AM EDT

Stock Overview

Symbol	KNE
Exchange	TSXV
Market Cap	17.8m
Last Price	\$0.155
52-Week	\$0.11 - \$0.235

11/29/2021 02:20 PM EST

Investor Relations

Harbor Access LLC
Graham Farrell
Managing Partner
130 King St. W
Suite 1900
Toronto, ON
T: (416) 842 9003
graham.farrell@harboraccessllc.com

Board of Directors

Mr. Mark Nawacki

Chairman

Marc Edwards

Director, Interim Chief Executive Officer

Rashieda Gluck

Director

Dr. Allan Mandelzys

Director

Kane Biotech Inc.

162-196 Innovation Drive
Winnipeg, Manitoba R3T 2N2
Canada

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.